Several anti-Th2 biologics have already shown impressive efficacy in reducing the rate of asthma exacerbations, particularly an anti-TSLP monoclonal antibody that, remarkably, lowered the annualized rates of exacerbations in patients with severe asthma, independent of their baseline blood eosinophil counts [95]. Here, TSLP is linked to asthma.